Japan's PeptiDream said it and Merck signed a collaboration agreement to produce targeted peptides for treating a variety of diseases. The arrangement is the latest in the biopharmaceutical's long list of deals with multinational drug makers.
China's WuXi PharmaTech is in play after a furious year in which it expanded from lab, contract research and manufacturing services into genomics, e-commerce and clinical screening testing, highlighting a percolating scene in newer Asian pharma and biotech that sets the stage for dealmaking.
FiercePharmaAsia combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.
Google's stealthy biotech Calico is setting up shop inside the Buck Institute for Research on Aging in Novato, CA, after hammering out the latest in a long lineup of deals to collaborate on a new generation of therapeutics.
Eisai and Nihon Medi-Physics plan to work together on one of Japan's three major dementia types, termed "dementia with Lewy bodies," meaning abnormal massing of protein inside nerve cells. The research is part of a broad cascade of efforts around the globe into diagnostics and treatments for dementia-related studies.
Shenzhen Hepalink Pharmaceutical said it has reached an agreement to develop and commercialize in Greater China a cardiovascular candidate from Resverlogix Corp. in a deal that could even include wider territorial sales if successful.
Generex's proprietary RapidMist buccal drug delivery device is finding a mark in the medical marijuana arena. The company announced its second medical marijuana outlicensing agreement, this time with Smoofi, a consultant to licensed U.S. medical and recreational marijuana operators and retail dispensaries.
Gilead Sciences reportedly plans to open a marketing office in Israel where it sells its products through NewPharm, an Israel drug store chain.
China's FDA is laying plans to work directly with its U.S. counterpart to learn the secrets of drug and medical-device regulation and bring China drug-making and other regulated industries up to international standards.
New Zealand research on a promising cancer drug that was discarded by previous companies was revived by U.S.-based Threshold Pharmaceuticals, which announced a promising showing in Phase I and II trials for treating a type of resistant lung cancer.